Assessment and treatment of abuse risk in opioid prescribing for chronic pain

Robert N Jamison, Juliana Serraillier, Edward Michna, Robert N Jamison, Juliana Serraillier, Edward Michna

Abstract

Opioid analgesics provide effective treatment for noncancer pain, but many physicians have concerns about adverse effects, tolerance, and addiction. Misuse of opioids is prominent in patients with chronic back pain and early recognition of misuse risk could help physicians offer adequate patient care while implementing appropriate levels of monitoring to reduce aberrant drug-related behaviors. In this review, we discuss opioid abuse and misuse issues that often arise in the treatment of patients with chronic back pain and present an overview of assessment and treatment strategies that can be effective in improving compliance with the use of prescription opioids for pain. Many persons with chronic back pain have significant medical, psychiatric and substance use comorbidities that affect treatment decisions and a comprehensive evaluation that includes a detailed history, physical, and mental health evaluation is essential. Although there is no "gold standard" for opioid misuse risk assessment, several validated measures have been shown to be useful. Controlled substance agreements, regular urine drug screens, and interventions such as motivational counseling have been shown to help improve patient compliance with opioids and to minimize aberrant drug-related behavior. Finally, we discuss the future of abuse-deterrent opioids and other potential strategies for back pain management.

References

    1. Chapman SL, Jamison RN, Sanders SH. Treatment helpfulness questionnaire: a measure of patient satisfaction with treatment modalities provided in chronic pain management programs. Pain. 1996;68(2-3):349–361.
    1. Linton S. The socioeconomic impact of chronic back pain: is anyone benefiting? Pain. 1998;75(2-3):163–168.
    1. Ohman M, Solderberg S, Lundman B. Hovering between suffering and enduring: the meaning of living with serious chronic illness. Qualitative Health Research. 2003;13(4):528–542.
    1. Soderberg S, Strand M, Haapala M, Lundman B. Living with a woman with fibromyalgia from the perspective of the husband. Journal of Advanced Nursing. 2003;42(2):143–150.
    1. Otis JD, Cardella LA, Kerns RD. The influence of family and culture on pain. In: Dworkin RH, Breitbart WS, editors. Psychosocial Aspects of Pain: A Handbook for Health Care Providers. Seattle, Wash, USA: IASP Press; 2004. pp. 29–45.
    1. Garofalo JP, Polatin P. Low back pain: an epidemic in industrialized countries. In: Gatchel RJ, Turk DC, editors. Psychosocial Factors in Pain: Clinical Perspectives. New York, NY, USA: The Guilford Press; 1999.
    1. Fordyce WE. Back Pain in the Workplace: Management of Disability in Nonspecific Conditions. Seattle, Wash, USA: IASP Press; 1995.
    1. Ehrlich GE. Back pain. Journal of Rheumatology. 2003;67:26–31.
    1. Frymoyer JW, Cats-Baril WL. An overview of the incidences and costs of low back pain. Orthopedic Clinics of North America. 1991;22(2):263–271.
    1. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain. 2000;84(1):95–103.
    1. Ferrari R, Russell AS. Regional musculoskeletal conditions: neck pain. Best Practice & Research Clinical Rheumatology. 2003;17(1):57–70.
    1. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. Journal of the American Medical Association. 2003;290(18):2443–2454.
    1. American Academy of Pain Medicine. Definitions related to the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Chevy Chase, Md, USA: American Academy of Pain Medicine; 2001.
    1. Chou R, Fanciullo GJ, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. Journal of Pain. 2009;10(2):113–130.
    1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51(1):8–19.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC, USA: American Psychiatric Association; 1994.
    1. Brown RL, Leonard T, Saunders LA, Papasouliotis O. The prevalence and detection of substance use disorders among inpatients ages 18 to 49: an opportunity for prevention. Preventive Medicine. 1998;27(1):101–110.
    1. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. Journal of Pain. 2006;7(4):225–235.
    1. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. Journal of the American Medical Association. 2007;297(3):249–251.
    1. Administration. SAaMHS. 2006 National Survey on Drug Use and Health, 2007.
    1. Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clinical Journal of Pain. 2002;18(supplement 4):S14–S27.
    1. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. Journal of Pain and Symptom Management. 2004;28(2):176–188.
    1. Leshner A. What does it mean that addiction is a brain disease? Monitor on Psychology. 2001;32:p. 19.
    1. Sees KL, Clark HW. Opioid use in the treatment of chronic pain: assessment of addiction. Journal of Pain and Symptom Management. 1993;8(5):257–264.
    1. Weissman DE, Haddox JD. Opioid pseudoaddiction: an iatrogenic syndrome. Pain. 1989;36(3):363–366.
    1. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. Journal of Pain and Symptom Management. 2008;35(2):214–228.
    1. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. Journal of Pain. 2002;3(5):377–384.
    1. Krantz MJ. Heterogeneous impact of methadone on the QTc interval: what are the practical implications? Journal of Addictive Diseases. 2008;27(4):5–9.
    1. Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Medicine. 2008;9(4):425–432.
    1. Deshpande A, Furlan AD, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database of Systematic Reviews. 2007;(3) Article ID CD004959.
    1. Kuijpers T, van Middelkoop M, Rubinstein SM, et al. A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. European Spine Journal. 2011;20:40–50.
    1. McNairy SL, Maruta T, Ivnik RJ. Prescription medication dependence and neuropsychologic function. Pain. 1984;18(2):169–177.
    1. Darton LA, Dilts SL. Opioids. In: Frances RJ, Miller SL, editors. Clinical Textbook of Addictive Disorders. 2nd edition. New York, NY, USA: The Guilford Press; 1998.
    1. Savage SR. Addiction in the treatment of pain: significance, recognition, and management. Journal of Pain and Symptom Management. 1993;8(5):265–278.
    1. Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clinical Journal of Pain. 2007;23(2):173–179.
    1. Robinson RC, Gatchel RJ, Polatin P, Deschner M, Noe C, Gajraj N. Screening for problematic prescription opioid use. Clinical Journal of Pain. 2001;17(3):220–228.
    1. Jamison RN, Butler SF, Budman SH, Edwards RR, Wasan AD. Gender differences in risk factors for aberrant prescription opioid use. Journal of Pain. 2010;11(4):312–320.
    1. Andersson GBJ. Epidemiological features of chronic low-back pain. The Lancet. 1999;354(9178):581–585.
    1. Bair M, Robinson R, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Archives of Internal Medicine. 2003;163(20):2433–2445.
    1. Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. Journal of Rheumatology. 2000;27(3):764–771.
    1. Katz JN, Stucki G, Lipson SJ, Fossel AH, Grobler LJ, Weinstein JN. Predictors of surgical outcome in degenerative lumbar spinal stenosis. Spine. 1999;24(21):2229–2233.
    1. Katz JN, Lipson SJ, Lew RA, et al. Lumbar laminectomy alone or with instrumented or noninstrumented arthrodesis in degenerative lumbar spinal stenosis: patient selection, costs, and surgical outcomes. Spine. 1997;22(10):1123–1131.
    1. Caldwell J, Hale M, Boyd R, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. Journal of Rheumatology. 1999;26(4):862–869.
    1. Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain—results of a double-blind placebo-controlled trial (MONTAS) Pain. 2002;97(3):223–233.
    1. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–380.
    1. von Korff M, Deyo RA. Potent opioids for chronic musculoskeletal pain: flying blind? Pain. 2004;109(3):207–209.
    1. Arkinstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC. Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. Pain. 1995;62(2):169–178.
    1. Moulin DE, Iezzi A, Amireh R, Sharpe WKJ, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. The Lancet. 1996;347(8995):143–147.
    1. Breckenridge J, Clark J. Patient characteristics associated with opioid versus nonsteroidal anti-inflammatory drug management of chronic low back pain. Journal of Pain. 2003;4(6):344–350.
    1. Rivest C, Katz JN, Ferrante FM, Jamison RN. Effects of epidural steroid injection on pain due to lumbar spinal stenosis or herniated disks: a prospective study. Arthritis Care and Research. 1998;11(4):291–297.
    1. Rooks DS, Huang J, Bierbaum BE, et al. Effect of preoperative exercise on measures of functional status in men and women undergoing total hip and knee arthroplasty. Arthritis Care and Research. 2006;55(5):700–708.
    1. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116(1-2):73–78.
    1. Wasan AD, Kaptchuk TJ, Davar G, Jamison RN. The association between psychopathology and placebo analgesia in patients with discogenic low back pain. Pain Medicine. 2006;7(3):217–228.
    1. Boersma K, Linton SJ. Screening to identify patients at risk: profiles of psychological risk factors for early intervention. Clinical Journal of Pain. 2005;21(1):38–43.
    1. Fishbain D. Approaches to treatment decisions for psychiatric comorbidity in the management of the chronic pain patient. Medical Clinics of North America. 1999;83(3):737–760.
    1. Wasan AD, Gudarz D, Jamison RN. The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain. 2005;117:450–461.
    1. Kessler R, McGonagle K, Zhao S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry. 1994;51(1):8–19.
    1. Cornelius J, Salloum I, Ehler J. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Archives of General Psychiatry. 1997;54(8):700–705.
    1. Sonne S, Brady K. Substance abuse and bipolar comorbidity. Psychiatric Clinics of North America. 1999;22(3):609–627.
    1. Brady K, Myrick H, Sonne S, editors. Comorbid Addiction and Affective Disorders. 2nd edition. Arlington, VA, USA: 1998.
    1. Hasin D, Liu X, Nunes E. Effects of major depression on remission and relapse of substance dependence. Archives of General Psychiatry. 2002;59(4):375–380.
    1. Quello S, Brady K, Sonne S. Mood disorders and substance use disorder: a complex comorbidity. Science and Practice Perspectives. 2005;3(1):13–21.
    1. Department of Justice, Drug Enforcement Administration. Dispensing controlled substances for the treatment of pain. Federal Register Notices. 2006;71:52715–52723. Docket No. DEA-286P.
    1. Hampton T. Experts point to lessons learned from controversy over rofecoxib safety. Journal of the American Medical Association. 2005;293(4):413–414.
    1. Helzer JE, Robins LN. The diagnostic interview schedule: its development, evaluations, and use. Social Psychiatry and Psychiatric Epidemiology. 1988;23:6–16.
    1. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. American Journal of Psychiatry. 1974;131(10):1121–1123.
    1. Selzer M. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. American Journal of Psychiatry. 1971;127(12):1653–1658.
    1. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Medicine. 2005;6(6):432–442.
    1. Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004;112(1-2):65–75.
    1. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R) Journal of Pain. 2008;9(4):360–372.
    1. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-validation of a screener to predict opioid misuse in chronic pain patients (SOAPP-R) Journal of Addiction Medicine. 2009;3(2):66–73.
    1. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130(1-2):144–156.
    1. Butler SF, Budman SH, Fanciullo GJ, Jamison R. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clinical Journal of Pain. 2010;26(9):770–776.
    1. Webster LR, Dove B. Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners. North Branch, Minn, USA: Sunrise River Press; 2007.
    1. Belgrade M. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. Journal of Pain. 2006;7(9):671–681.
    1. Passik SD, Kirsh KL, Whitcomb RK, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clinical Therapeutics. 2004;26(4):552–561.
    1. Coambs RB, Jarry JL, Santhiapillai AS, Abrahamsohn RV, Atance CM. The SISAP: a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain within general medical practice. Pain Research and Management. 1996;1(2):155–162.
    1. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clinical Journal of Pain. 1999;15(3):184–191.
    1. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clinical Journal of Pain. 2002;18(supplement 4):S76–S82.
    1. Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Medicine. 2009;10(8):1434–1441.
    1. Munsey C. Medicine or menace: psychologists' research can inform the growing debate over legalizing marijuana. Monitor on Psychology. 2010;41(6):50–55.
    1. Gourlay D, Heit H, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Medicine. 2005;6(2):107–112.
    1. Cifuentes M, Webster B, Genevay S, Pransky G. The course of opioid prescribing for a new episode of disabling low back pain: opioid features and dose escalation. Pain. 2010;151(1):22–29.
    1. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the malaysian market. American Journal of Drug and Alcohol Abuse. 2009;35(2):68–72.
    1. Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clinical Therapeutics. 2010;32(5):844–860.
    1. Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. Pain. 2010;150(3):390–400.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa